Cite
MLA Citation
J F Colombel et al.. “DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).” Journal of Crohn's and colitis, vol. 17, n.d., pp. i161–i162. http://access.bl.uk/ark:/81055/vdc_100179843738.0x00003a